{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T13:33:49Z","timestamp":1750080829030,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Study Support Center at Wakayama Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pre-treatment albumin-bilirubin grade is a useful biomarker for predicting prognosis in patients receiving immune checkpoint inhibitors for advanced malignancies. We evaluated the prognostic impact of pre-treatment albumin-bilirubin grade in patients receiving pembrolizumab for metastatic urothelial carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter retrospective study, we calculated pre-treatment albumin-bilirubin scores of 96 patients who received pembrolizumab for metastatic urothelial carcinoma between January 2018 and March 2022. Patients were classified according to albumin-bilirubin grade. Progression-free survival and cancer-specific survival were compared between the groups. To evaluate the prognostic impact of pre-treatment albumin-bilirubin grade, we also performed Cox proportional regression analyses for progression-free survival and cancer-specific survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median pre-treatment albumin bilirubin score was \u22122.52 (quartile: \u22122.76 to \u22122.10), and albumin-bilirubin grade was grade 1 in 37 patients (39%), grade 2a in 30 patients (31%), 2b in 22 patients (23%) and grade 3 in 7 patients (7%). The median progression-free survival and cancer-specific survival were 2 and 7\u00a0months, respectively. Progression-free survival and cancer-specific survival were significantly different between the albumin-bilirubin grade groups (P\u00a0&amp;lt;\u00a00.01 and P\u00a0&amp;lt;\u00a00.01, respectively) and prognosis became poorer as albumin-bilirubin grade increased. High albumin-bilirubin grade was shown in multivariable Cox proportional analyses to be independently associated with both poor progression-free survival and poor cancer-specific survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High pre-treatment albumin-bilirubin grade could be a significant independent predictor of poor prognosis in patients receiving pembrolizumab for advanced urothelial carcinoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad069","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T09:55:16Z","timestamp":1687773316000},"page":"845-850","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-6164","authenticated-orcid":false,"given":"Shimpei","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Urology, Wakayama Medical University , 811-1 Kimiidera, Wakayama 641-0012 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Medical University , 811-1 Kimiidera, Wakayama 641-0012 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Medical University , 811-1 Kimiidera, Wakayama 641-0012 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Mashima","sequence":"additional","affiliation":[{"name":"Department of Urology, Kinan Hospital , 46-70 Shinjyo, Tanabe, Wakayama 646-8588 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Rinku General Medical Center , 2-23 Rinkuoraikita, Izumisano, Osaka 598-8577 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Miyai","sequence":"additional","affiliation":[{"name":"Department of Urology, Kishiwada Tokushukai Hospital , 4-27-1 Kamori cho, Kishiwada, Osaka 596-0042 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Rosai Hospital , 93-1 Kinomoto, Wakayama 640-8505 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Medical University , 811-1 Kimiidera, Wakayama 641-0012 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Medical University , 811-1 Kimiidera, Wakayama 641-0012 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"2023090116055467200_ref1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2023090116055467200_ref2","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1038\/s41598-021-94336-9","article-title":"Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"2023090116055467200_ref3","doi-asserted-by":"crossref","first-page":"100348","DOI":"10.1016\/j.esmoop.2021.100348","article-title":"Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy","volume":"7","author":"Takada","year":"2022","journal-title":"ESMO Open"},{"key":"2023090116055467200_ref4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023090116055467200_ref5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"2023090116055467200_ref6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fimmu.2019.00293","article-title":"Causes and consequences of innate immune dysfunction in cirrhosis","volume":"10","author":"Irvine","year":"2019","journal-title":"Front Immunol"},{"key":"2023090116055467200_ref7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023090116055467200_ref8","doi-asserted-by":"crossref","first-page":"746922","DOI":"10.3389\/fonc.2022.746922","article-title":"Recent advances in medical therapy for urological cancers","volume":"12","author":"Yuasa","year":"2022","journal-title":"Front Oncol"},{"key":"2023090116055467200_ref9","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"2023090116055467200_ref10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-021-03000-8","article-title":"Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2023090116055467200_ref11","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1245\/s10434-022-11445-z","article-title":"Association of Albumin-Bilirubin Grade and Myosteatosis with its prognostic significance for patients with colorectal cancer","volume":"29","author":"Koh","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2023090116055467200_ref12","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1245\/s10434-021-09593-9","article-title":"Clinical significance of preoperative albumin-bilirubin grade in pancreatic cancer","volume":"28","author":"Imamura","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2023090116055467200_ref13","doi-asserted-by":"crossref","first-page":"21199","DOI":"10.1038\/s41598-021-00509-x","article-title":"FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab","volume":"11","author":"Kawashima","year":"2021","journal-title":"Sci Rep"},{"key":"2023090116055467200_ref14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5114\/ceh.2018.78119","article-title":"Immunodeficiency caused by cirrhosis","volume":"4","author":"Tuchendler","year":"2018","journal-title":"Clin Exp Hepatol"},{"key":"2023090116055467200_ref15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1110\/ps.28702","article-title":"Structural insights into human serum albumin-mediated prostaglandin catalysis","volume":"11","author":"Yang","year":"2002","journal-title":"Protein Sci"},{"key":"2023090116055467200_ref16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm.3553","article-title":"Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis","volume":"20","author":"Arroyo","year":"2014","journal-title":"Nat Med"},{"key":"2023090116055467200_ref17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hep.27644","article-title":"Prostaglandin E2 -mediated immunosuppression and the role of albumin as its modulator","volume":"61","author":"Choe","year":"2015","journal-title":"Hepatology"},{"key":"2023090116055467200_ref18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cgh.2017.08.027","article-title":"Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease","volume":"16","author":"China","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023090116055467200_ref19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lungcan.2020.04.034","article-title":"Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy","volume":"145","author":"Takada","year":"2020","journal-title":"Lung Cancer"},{"key":"2023090116055467200_ref20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.11.026","article-title":"Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors","volume":"152","author":"Takamori","year":"2021","journal-title":"Lung Cancer"},{"key":"2023090116055467200_ref21","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1038\/s41598-021-95061-z","article-title":"Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study","volume":"11","author":"Taguchi","year":"2021","journal-title":"Sci Rep"},{"key":"2023090116055467200_ref22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.20334","article-title":"Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats","volume":"40","author":"Wang","year":"2004","journal-title":"Hepatology"},{"key":"2023090116055467200_ref23","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1089\/ars.2007.1807","article-title":"Therapeutic applications of bilirubin and biliverdin in transplantation","volume":"9","author":"Ollinger","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"2023090116055467200_ref24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.amjsurg.2007.12.010","article-title":"Hyperbilirubinemia: a risk factor for infection in the surgical intensive care unit","volume":"195","author":"Field","year":"2008","journal-title":"Am J Surg"},{"key":"2023090116055467200_ref25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.181.3.1887","article-title":"Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis","volume":"181","author":"Liu","year":"2008","journal-title":"J Immunol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/9\/845\/51308911\/hyad069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/9\/845\/51308911\/hyad069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T16:07:03Z","timestamp":1693584423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/9\/845\/7206813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,6,24]]},"published-print":{"date-parts":[[2023,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad069","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,6,24]]}}}